WO2007127749A3 - Predicting mortality and detecting severe disease - Google Patents
Predicting mortality and detecting severe disease Download PDFInfo
- Publication number
- WO2007127749A3 WO2007127749A3 PCT/US2007/067333 US2007067333W WO2007127749A3 WO 2007127749 A3 WO2007127749 A3 WO 2007127749A3 US 2007067333 W US2007067333 W US 2007067333W WO 2007127749 A3 WO2007127749 A3 WO 2007127749A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- severe disease
- predicting mortality
- detecting severe
- mortality
- detecting
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17177530.7A EP3255432B1 (en) | 2006-04-24 | 2007-04-24 | Predicting mortality and detecting severe disease |
DE602007008224T DE602007008224D1 (en) | 2006-04-24 | 2007-04-24 | PREDICTION OF LETALITY AND DETECTION OF SERIOUS DISEASES |
AU2007244927A AU2007244927B2 (en) | 2006-04-24 | 2007-04-24 | Predicting mortality and detecting severe disease |
CA2650201A CA2650201C (en) | 2006-04-24 | 2007-04-24 | Predicting mortality and detecting severe disease |
ES07761219T ES2351623T3 (en) | 2006-04-24 | 2007-04-24 | PREDICTION OF MORTALITY AND DETECTION OF A SERIOUS ILLNESS. |
EP07761219A EP2010912B1 (en) | 2006-04-24 | 2007-04-24 | Predicting mortality and detecting severe disease |
JP2009507931A JP5383480B2 (en) | 2006-04-24 | 2007-04-24 | Predict fatality and detect serious disease |
AT07761219T ATE476657T1 (en) | 2006-04-24 | 2007-04-24 | PREDICTION OF LETHALITY AND DETECTION OF SERIOUS DISEASES |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79435406P | 2006-04-24 | 2006-04-24 | |
US60/794,354 | 2006-04-24 | ||
US80036206P | 2006-05-15 | 2006-05-15 | |
US60/800,362 | 2006-05-15 | ||
US90460807P | 2007-03-02 | 2007-03-02 | |
US60/904,608 | 2007-03-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007127749A2 WO2007127749A2 (en) | 2007-11-08 |
WO2007127749A3 true WO2007127749A3 (en) | 2008-03-20 |
Family
ID=38656334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/067333 WO2007127749A2 (en) | 2006-04-24 | 2007-04-24 | Predicting mortality and detecting severe disease |
Country Status (12)
Country | Link |
---|---|
US (7) | US7998683B2 (en) |
EP (5) | EP3255432B1 (en) |
JP (4) | JP5383480B2 (en) |
AT (2) | ATE527544T1 (en) |
AU (1) | AU2007244927B2 (en) |
CA (1) | CA2650201C (en) |
DE (1) | DE602007008224D1 (en) |
DK (3) | DK2386860T3 (en) |
ES (4) | ES2351623T3 (en) |
HK (3) | HK1164443A1 (en) |
PL (2) | PL2848938T3 (en) |
WO (1) | WO2007127749A2 (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7432060B2 (en) | 2000-11-09 | 2008-10-07 | The Brigham And Women's Hospital, Inc. | Methods for diagnosis of cardiovascular disease |
HUE027779T2 (en) | 2002-05-09 | 2016-11-28 | Brigham & Womens Hospital Inc | 1L1RL-1 as a cardiovascular disease marker |
EP1731910A1 (en) * | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
EP3255432B1 (en) | 2006-04-24 | 2019-01-23 | Critical Care Diagnostics, Inc. | Predicting mortality and detecting severe disease |
US20090305265A1 (en) * | 2006-04-27 | 2009-12-10 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
EP3059594A1 (en) | 2006-05-01 | 2016-08-24 | Critical Care Diagnostics, Inc. | Prognosis of cardiovascular disease |
DK2019965T3 (en) * | 2006-05-02 | 2015-07-20 | Critical Care Diagnostics Inc | DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease |
EP2447285A3 (en) * | 2006-05-25 | 2013-01-16 | Momenta Pharmaceuticals, Inc. | Low molecular weight heparin composition and uses thereof |
US11389080B2 (en) | 2007-11-28 | 2022-07-19 | Intervet Inc. | System and method for diagnosis of bovine diseases using auscultation analysis |
WO2009100907A1 (en) * | 2008-02-14 | 2009-08-20 | Dianeering Diagnostics Engineering And Research Gmbh | Means and methods for assessing the risk of patients presenting to emergency departments based on very low concentrations of troponin i or t or using a combination of markers |
EP2242494A4 (en) * | 2008-02-20 | 2013-01-02 | Momenta Pharmaceuticals Inc | Methods of making low molecular weight heparin compositions |
DK2660599T3 (en) * | 2008-04-18 | 2014-12-08 | Critical Care Diagnostics Inc | PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS |
EP2141499A1 (en) * | 2008-07-02 | 2010-01-06 | Apoptec AG | COPD diagnosis |
US20100099958A1 (en) * | 2008-10-16 | 2010-04-22 | Fresenius Medical Care Holdings Inc. | Method of identifying when a patient undergoing hemodialysis is at increased risk of death |
US9883799B2 (en) * | 2008-10-16 | 2018-02-06 | Fresenius Medical Care Holdings, Inc. | Method of identifying when a patient undergoing hemodialysis is at increased risk of death |
US10064580B2 (en) | 2008-11-07 | 2018-09-04 | Intervet Inc. | System and method for determining antibiotic effectiveness in respiratory diseased animals using auscultation analysis |
JP2012063139A (en) * | 2008-12-15 | 2012-03-29 | Hokkaido Univ | Diagnostic method for pancreatic cancer using glycan analysis |
JP2012063140A (en) * | 2008-12-15 | 2012-03-29 | Hokkaido Univ | Diagnostic method for lung cancer using glycan analysis |
EP2480237A1 (en) * | 2009-09-23 | 2012-08-01 | Momenta Pharmaceuticals, Inc. | Methods of treatment with a low molecular weight heparin composition |
US9274126B2 (en) * | 2009-11-13 | 2016-03-01 | Bg Medicine, Inc. | Risk factors and prediction of myocardial infarction |
CA2788760A1 (en) * | 2010-03-26 | 2011-09-29 | Pronota N.V. | Ltbp2 as a biomarker for renal dysfunction |
MX2012011667A (en) | 2010-04-09 | 2013-03-05 | Critical Care Diagnostics Inc | Soluble human st-2 antibodies and assays. |
JP2011232164A (en) * | 2010-04-27 | 2011-11-17 | Keio Gijuku | Liver disease marker, method and device for measuring the same, and method for verifying medicine |
US20110295613A1 (en) * | 2010-05-28 | 2011-12-01 | Martin Coyne | Inpatient utilization management system and method |
EP2635904A1 (en) * | 2010-11-01 | 2013-09-11 | B.R.A.H.M.S GmbH | Prognosis and risk assessment of patients with non-specific complaints |
GB201021289D0 (en) * | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
EP2646823B9 (en) | 2010-12-02 | 2017-02-22 | Fresenius Medical Care Holdings, Inc. | Method of identifying when a patient undergoing hemodialysis is at increased risk of death |
EP3605104B1 (en) | 2011-03-17 | 2021-09-15 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
AU2012284039B2 (en) | 2011-07-18 | 2017-03-30 | Critical Care Diagnostics, Inc. | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
US20130157290A1 (en) * | 2011-12-16 | 2013-06-20 | Yves Levy | Soluble st2 as a marker for disease |
UY34813A (en) | 2012-05-18 | 2013-11-29 | Amgen Inc | ANTIGEN UNION PROTEINS DIRECTED AGAINST ST2 RECEIVER |
EP3434260A1 (en) * | 2012-05-18 | 2019-01-30 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of ventricular tachyarrhythmia event |
CN104737023B (en) | 2012-08-16 | 2017-07-28 | 重症监护诊断股份有限公司 | The method of risk of hypertension is suffered from prediction |
CN111834009A (en) * | 2012-08-21 | 2020-10-27 | 重症监护诊断股份有限公司 | Multi-marker risk stratification |
ES2731824T3 (en) | 2013-02-06 | 2019-11-19 | Intervet Inc | System to determine the efficacy of antibiotics in respiratory diseases by auscultation analysis |
MX2016009060A (en) | 2014-01-10 | 2016-09-09 | Critical Care Diagnostics Inc | Methods and systems for determining risk of heart failure. |
CA3103560C (en) | 2014-09-26 | 2023-01-17 | Somalogic, Inc. | Cardiovascular risk event prediction and uses thereof |
CN107110871B (en) | 2014-10-29 | 2019-09-27 | 豪夫迈·罗氏有限公司 | Biomarker for dead risk profile |
US11708608B2 (en) | 2014-11-10 | 2023-07-25 | Genentech, Inc. | Therapeutic and diagnostic methods for IL-33-mediated disorders |
EA201791029A1 (en) | 2014-11-10 | 2017-12-29 | Дженентек, Инк. | ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION |
US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
CN106952043B (en) * | 2017-03-23 | 2021-04-13 | 国家电网公司客户服务中心 | Planned power failure sensitivity assessment method and device |
CN108982871B (en) * | 2018-07-19 | 2021-09-24 | 北京市心肺血管疾病研究所 | Application of serum sST2 in children dilated cardiomyopathy prognosis |
CA3174680A1 (en) | 2020-03-13 | 2021-09-16 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
WO2023201054A1 (en) * | 2022-04-15 | 2023-10-19 | Memorial Sloan-Kettering Cancer Center | Multi-modal machine learning to determine risk stratification |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040133079A1 (en) * | 2003-01-02 | 2004-07-08 | Mazar Scott Thomas | System and method for predicting patient health within a patient management system |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4208479A (en) * | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
US5206140A (en) * | 1988-06-24 | 1993-04-27 | Research Corporation Technologies, Inc. | Assay for soluble crosslinked fibrin polymers |
JPH0731479Y2 (en) | 1989-06-02 | 1995-07-19 | 内橋エステック株式会社 | Thermal fuse |
US5217899A (en) | 1990-08-24 | 1993-06-08 | The General Hospital Corporation | Cell stretching apparatus |
JP2665850B2 (en) | 1991-11-14 | 1997-10-22 | 塩野義製薬株式会社 | Monoclonal antibody recognizing the C-terminus of hBNP |
GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
JPH0731479A (en) | 1993-02-23 | 1995-02-03 | Shinichi Tominaga | Dna of coding murine st2l, expression product of the same dna and production of expression product by expressing the same dna |
US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
JP2001500724A (en) | 1996-08-23 | 2001-01-23 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | T1 receptor-like ligand II |
EP0981619A1 (en) | 1997-02-28 | 2000-03-01 | Human Genome Sciences, Inc. | T1/st2-receptor ligand iii |
DE19711932A1 (en) | 1997-03-21 | 1998-09-24 | Anne Katrin Dr Werenskiold | An in vitro method for predicting the course of disease of patients with breast cancer and / or for diagnosing a breast carcinoma |
DK1003501T3 (en) | 1997-04-02 | 2005-07-18 | Brigham & Womens Hospital | Use of a means to reduce the risk of cardiovascular disease |
EP0988552B1 (en) | 1997-06-10 | 2010-11-24 | Lpath, Inc. | Methods for early detection of heart disease |
WO1999013331A1 (en) | 1997-09-11 | 1999-03-18 | Shionogi & Co., Ltd. | Immunoassay method for bnp |
GB9727172D0 (en) | 1997-12-24 | 1998-02-25 | Univ Glasgow | Reagents specific for st2l and uses therefor |
GB9827348D0 (en) | 1998-12-12 | 1999-02-03 | Univ Leicester | Natriuretic peptide |
EP1140137A2 (en) | 1998-12-18 | 2001-10-10 | Scios Inc. | Method for detection and use of differentially expressed genes in disease states |
WO2000073498A1 (en) | 1999-06-02 | 2000-12-07 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
FR2795823B1 (en) | 1999-07-01 | 2001-11-23 | Inst Nat Sante Rech Med | METHODS AND KITS FOR DIAGNOSING OR MONITORING SYNOVIAL OR OSTEOARTICULAR PATHOLOGY INCLUDING THE USE OF A SPECIFIC MARKER FOR THE DEGRADATION OF SYNOVIAL TISSUE |
US6677356B1 (en) | 1999-08-24 | 2004-01-13 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
WO2001070817A1 (en) | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
FR2807170B1 (en) | 2000-03-30 | 2002-06-28 | Sipal | ELASTIC HINGE WITH REDUCED FRICTION |
AU8513901A (en) | 2000-08-22 | 2002-03-04 | Brigham And Women's Hospital | Diagnosis and treatment of cardiovascular conditions |
US7432060B2 (en) | 2000-11-09 | 2008-10-07 | The Brigham And Women's Hospital, Inc. | Methods for diagnosis of cardiovascular disease |
US6537221B2 (en) | 2000-12-07 | 2003-03-25 | Koninklijke Philips Electronics, N.V. | Strain rate analysis in ultrasonic diagnostic images |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
EP2261669A1 (en) | 2001-05-04 | 2010-12-15 | Alere San Diego, Inc. | Diagnostic markers of acute coronary syndromes and methods of use thereof |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
WO2003022987A2 (en) | 2001-07-26 | 2003-03-20 | Eos Biotechnology, Inc. | Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection |
US6810284B1 (en) | 2001-11-21 | 2004-10-26 | Pacesetter, Inc. | Implantable cardiac stimulation system and method for monitoring diastolic function |
HUE027779T2 (en) | 2002-05-09 | 2016-11-28 | Brigham & Womens Hospital Inc | 1L1RL-1 as a cardiovascular disease marker |
MXPA03004105A (en) * | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Making a prognosis in cases of cardiac disease using a combination of markers. |
AU2003239544A1 (en) * | 2002-05-24 | 2003-12-12 | Tularik Inc. | Amplification and overexpression of oncogenes |
US8263325B2 (en) * | 2002-11-15 | 2012-09-11 | Ottawa Heart Institute Research Corporation | Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis |
AU2003299441A1 (en) | 2002-12-19 | 2004-07-14 | Centre National De La Recherche Scientifique - Cnrs | Nf-hev compositions and methods of use |
US20040220155A1 (en) | 2003-03-28 | 2004-11-04 | Pharmacia Corporation | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
US20050123451A1 (en) | 2003-10-31 | 2005-06-09 | Hiroshi Nomura | System and apparatus for body fluid analysis using surface-textured optical materials |
EP2186913B1 (en) | 2003-11-26 | 2016-02-10 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
CA2549236C (en) | 2003-12-05 | 2017-06-13 | The Cleveland Clinic Foundation | Risk markers for cardiovascular disease |
US20050196817A1 (en) * | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
JP2005291899A (en) * | 2004-03-31 | 2005-10-20 | Akira Matsumori | Examination method of heart disease |
US20060196817A1 (en) | 2004-12-17 | 2006-09-07 | Clearwater Systems Corporation | Method and apparatus for treating fluids |
PT1849009E (en) | 2005-01-24 | 2009-01-14 | Hoffann La Roche Ag F | The use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs. |
EP1731910A1 (en) | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
US20070021977A1 (en) * | 2005-07-19 | 2007-01-25 | Witt Biomedical Corporation | Automated system for capturing and archiving information to verify medical necessity of performing medical procedure |
JP4820192B2 (en) | 2006-03-17 | 2011-11-24 | 一般財団法人化学及血清療法研究所 | Measurement and use of ADAMTS13 in acute coronary syndromes |
EP3255432B1 (en) | 2006-04-24 | 2019-01-23 | Critical Care Diagnostics, Inc. | Predicting mortality and detecting severe disease |
US20090305265A1 (en) | 2006-04-27 | 2009-12-10 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
EP3059594A1 (en) | 2006-05-01 | 2016-08-24 | Critical Care Diagnostics, Inc. | Prognosis of cardiovascular disease |
DK2019965T3 (en) | 2006-05-02 | 2015-07-20 | Critical Care Diagnostics Inc | DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease |
WO2007130627A2 (en) | 2006-05-04 | 2007-11-15 | The Brigham And Women's Hospital, Inc. | Il-33 in the treatment and diagnosis of diseases and disorders |
RU2312591C1 (en) | 2006-06-14 | 2007-12-20 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" | Method for predicting the development of the risk of crib death in patients with left- and right-ventricular extrasystolia |
US20080233191A1 (en) | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
JP2010526555A (en) | 2007-05-11 | 2010-08-05 | タフツ・メディカル・センター | Polynucleotides associated with age-related macular degeneration and methods for assessing patient risk |
GB0713404D0 (en) | 2007-07-11 | 2007-08-22 | Integra Sp Ipr Ltd | Altio graph |
US20100267062A1 (en) | 2007-09-26 | 2010-10-21 | Norbert Frey | Osteopontin as Novel Prognostic Biomarker for Heart Failure |
FR2923029B1 (en) | 2007-10-26 | 2009-11-20 | Minima | GLASSES OF TYPE WITHOUT ENTOURAGE WITH WIRED BRANCHES |
DK2660599T3 (en) | 2008-04-18 | 2014-12-08 | Critical Care Diagnostics Inc | PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS |
ES2431358T3 (en) | 2008-11-11 | 2013-11-26 | B.R.A.H.M.S Gmbh | Prognosis and risk assessment in patients suffering from heart failure by determining the concentration of ADM |
US9274126B2 (en) | 2009-11-13 | 2016-03-01 | Bg Medicine, Inc. | Risk factors and prediction of myocardial infarction |
MX2012011667A (en) | 2010-04-09 | 2013-03-05 | Critical Care Diagnostics Inc | Soluble human st-2 antibodies and assays. |
EP2635904A1 (en) | 2010-11-01 | 2013-09-11 | B.R.A.H.M.S GmbH | Prognosis and risk assessment of patients with non-specific complaints |
RU2452394C1 (en) | 2010-11-09 | 2012-06-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет | Method of predicting risk of death of patients with chronic heart failure |
EP3605104B1 (en) | 2011-03-17 | 2021-09-15 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
AU2012284039B2 (en) | 2011-07-18 | 2017-03-30 | Critical Care Diagnostics, Inc. | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
EP3434260A1 (en) | 2012-05-18 | 2019-01-30 | Critical Care Diagnostics, Inc. | Methods for treating or predicting risk of ventricular tachyarrhythmia event |
CN104737023B (en) | 2012-08-16 | 2017-07-28 | 重症监护诊断股份有限公司 | The method of risk of hypertension is suffered from prediction |
CN111834009A (en) | 2012-08-21 | 2020-10-27 | 重症监护诊断股份有限公司 | Multi-marker risk stratification |
JP6178687B2 (en) | 2013-09-27 | 2017-08-09 | 富士機械工業株式会社 | Gravure coating equipment |
MX2016009060A (en) | 2014-01-10 | 2016-09-09 | Critical Care Diagnostics Inc | Methods and systems for determining risk of heart failure. |
USD770057S1 (en) | 2014-04-14 | 2016-10-25 | Critical Care Diagnostics, Inc. | Blood test kit |
US9934249B2 (en) | 2014-06-03 | 2018-04-03 | Conduent Business Machines Services, Llc | Systems and methods for context-aware and personalized access to visualizations of road events |
USD800333S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
USD800332S1 (en) | 2014-09-23 | 2017-10-17 | Critical Care Diagnostics, Inc. | Blood test kit |
US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2007
- 2007-04-24 EP EP17177530.7A patent/EP3255432B1/en not_active Not-in-force
- 2007-04-24 DK DK11177461.8T patent/DK2386860T3/en active
- 2007-04-24 WO PCT/US2007/067333 patent/WO2007127749A2/en active Application Filing
- 2007-04-24 EP EP07761219A patent/EP2010912B1/en active Active
- 2007-04-24 EP EP11177461.8A patent/EP2386860B1/en not_active Not-in-force
- 2007-04-24 DK DK14188319.9T patent/DK2848938T3/en active
- 2007-04-24 PL PL14188319T patent/PL2848938T3/en unknown
- 2007-04-24 EP EP10171764A patent/EP2241888B1/en active Active
- 2007-04-24 US US11/789,169 patent/US7998683B2/en active Active
- 2007-04-24 DE DE602007008224T patent/DE602007008224D1/en active Active
- 2007-04-24 EP EP14188319.9A patent/EP2848938B1/en not_active Not-in-force
- 2007-04-24 AT AT10171764T patent/ATE527544T1/en active
- 2007-04-24 CA CA2650201A patent/CA2650201C/en not_active Expired - Fee Related
- 2007-04-24 JP JP2009507931A patent/JP5383480B2/en not_active Expired - Fee Related
- 2007-04-24 ES ES07761219T patent/ES2351623T3/en active Active
- 2007-04-24 ES ES10171764T patent/ES2378314T3/en active Active
- 2007-04-24 DK DK10171764.3T patent/DK2241888T3/en active
- 2007-04-24 AU AU2007244927A patent/AU2007244927B2/en not_active Ceased
- 2007-04-24 PL PL11177461T patent/PL2386860T4/en unknown
- 2007-04-24 ES ES11177461.8T patent/ES2529618T3/en active Active
- 2007-04-24 ES ES14188319.9T patent/ES2646142T3/en active Active
- 2007-04-24 AT AT07761219T patent/ATE476657T1/en active
-
2011
- 2011-07-08 US US13/179,173 patent/US8617825B2/en active Active
- 2011-10-26 US US13/282,111 patent/US9568481B2/en active Active
-
2012
- 2012-04-26 JP JP2012100940A patent/JP5806165B2/en active Active
- 2012-05-16 HK HK12104804.4A patent/HK1164443A1/en not_active IP Right Cessation
-
2013
- 2013-03-07 US US13/787,975 patent/US9057733B2/en not_active Expired - Fee Related
-
2015
- 2015-09-03 JP JP2015173815A patent/JP6214604B2/en active Active
- 2015-09-17 HK HK18107615.0A patent/HK1248311B/en not_active IP Right Cessation
- 2015-09-17 HK HK15109122.5A patent/HK1208724A1/en not_active IP Right Cessation
-
2017
- 2017-01-19 US US15/410,155 patent/US10067146B2/en active Active
- 2017-09-19 JP JP2017178945A patent/JP2017215347A/en active Pending
-
2018
- 2018-08-13 US US16/101,939 patent/US11016103B2/en active Active
-
2021
- 2021-04-27 US US17/241,303 patent/US20210255200A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040133079A1 (en) * | 2003-01-02 | 2004-07-08 | Mazar Scott Thomas | System and method for predicting patient health within a patient management system |
Non-Patent Citations (3)
Title |
---|
TSUCHIYA ET AL.: "Expression and Regulation of ST2 an interleukin-1 Receprtor Family member, in cardinmyocytes and myocardial infarction", CIRCULATION, vol. 106, 2002, pages 2961 - 2966, XP008013076 * |
TSUCHIYA ET AL.: "Th1, Th2 and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma unspecified comparison AILD, ALCL, lymphoblastic lymphoma and ATLL", BLOOD, vol. 103, 2004, pages 236 - 241, XP008131665 * |
WEINBERG ET AL.: "Identification of Serum Schluble ST2 receptor as a novel heart failure biomarker", CIRCULATION, vol. 107, 2003, pages 721 - 726, XP002985431 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007127749A3 (en) | Predicting mortality and detecting severe disease | |
WO2008008284A3 (en) | Cancer biomarkers and methods of use threof | |
WO2005041893A3 (en) | Detection of acute myocardial infarction biomarkers | |
JP2009501333A5 (en) | ||
WO2006128192A3 (en) | Use of free circulating dna for diagnosis, prognosis, and treatment of cancer | |
WO2008135862A3 (en) | Devices and methods for detecting analytes | |
WO2006026020A3 (en) | Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin | |
WO2010053587A3 (en) | Methods of monitoring conditions by sequence analysis | |
WO2010033371A3 (en) | Molecular markers for lung and colorectal carcinomas | |
WO2008041953A3 (en) | Dengue diagnosis and treatment | |
WO2006113529A3 (en) | Diagnosis of sepsis | |
WO2008135564A3 (en) | Assays | |
MX2009006159A (en) | Test element with referencing. | |
EP3156925A3 (en) | Copd biomarker signatures | |
WO2007133586A3 (en) | Systems and methods for developing diagnostic tests based on biomarker information from legacy clinical sample sets | |
WO2008109075A3 (en) | Biomarkers and methods for determining sensitivity to ctla-4 antagonists | |
FR2896587B1 (en) | SENSOR FOR DETECTING THE STATE OF A LIQUID. | |
ATE504002T1 (en) | DETECTION AND PREDICTION OF PREMATURE BIRTH | |
WO2009055382A3 (en) | One-step immunoassays exhibiting increased sensitivity and specificity | |
WO2014140974A3 (en) | System and method for determining risk of diabetes based on biochemical marker analysis | |
WO2004057336A3 (en) | Use of nicotinamide n-methyltransferase as a marker for colorectal cancer | |
WO2008131261A3 (en) | Peptide biomarkers of cardiovascular disease | |
SE0602683L (en) | Diagnostic method | |
WO2007078841A3 (en) | Diagnosis of sepsis | |
NZ605561A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07761219 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2650201 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009507931 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007244927 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007761219 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007244927 Country of ref document: AU Date of ref document: 20070424 Kind code of ref document: A |